Acyl-CoA synthetase (ACS) ligates fatty acid and CoA to produce acyl-CoA, an essential molecule in fatty acid metabolism and cell proliferation. ACS5 is a recently characterized ACS isozyme highly expressed in proliferating 3T3-L1 cells. Molecular characterization of the human ACS5 gene revealed that the gene is located on chromosome 10q25.1-q25.2, spans approximately 46 kb, comprises 21 exons and 22 introns, and encodes a 683 amino acid protein. Two major ACS5 transcripts of 2.5-and 3.7-kb are distributed in a wide range of tissues with the highest expression in uterus and spleen. Markedly increased levels of ACS5 transcripts were detected in a glioma line, A172 cells, and primary gliomas of grade IV malignancy, while ACS5 expression was found to be low in normal brain. Immunohistochemical analysis also revealed strong immunostaining with an anti-ACS5 antibody in glioblastomas. U87MG glioma cells infected with an adenovirus encoding ACS5 displayed induced cell growth on exposure to palmitate. Consistent with the induction of cell growth, the virus infected cells displayed induced uptake of palmitate. These results demonstrate a novel fatty acid-induced glioma cell growth mediated by ACS5. Oncogene (2000) 19, 5919 ± 5925.
Introduction
Acyl-CoA synthetase (ACS, EC6.2.1.3) catalyzes the formation of acyl-CoA from fatty acid, ATP and CoA. This reaction is essential in mammalian fatty acid metabolism, including the catabolic pathway for the degradation of fatty acid via the b-oxidation system and the anabolic pathway for the synthesis of cellular lipids. ACS also plays a role in cell proliferation by providing acyl-CoAs for the synthesis of membrane phospholipids. Tomoda et al. (1991) have shown that speci®c inhibitors of ACS, triacsins, profoundly reduce the synthesis of cellular phospholipids, and that this blockade of acyl-CoA synthesis results in the inhibition of cell proliferation.
In addition to fatty acid metabolism, ACS mediates the transportation of fatty acids into cells by cooperating with fatty acid transporter (Schaer and Lodish, 1994) . By expression cloning, Schaer and Lodish identi®ed two proteins that promote uptake of long chain fatty acid into 3T3-L1 cells: one is an integral plasma membrane protein of 63 kDa, termed fatty acid transport protein, which later turned out to be identical to very long chain acyl-CoA synthetase (Coe et al., 1999) ; and the other is identical to ACS1 (Suzuki et al., 1990) . These studies suggest that ACS facilitates the uptake of long chain fatty acid into cells. Furthermore, recent studies by Yagasaki et al. (1999) have identi®ed the human ACS2 gene as a new ets variant gene 6 (ETV6) fusion partner in a patient with refractory anemia with excess blasts with basophilia, a patient with acute myelogenous leukemia with eosinophilia and a patient with acute eosinophilic leukemia. The ETV6/ACS2 fusion in these patients disrupts both the ACS2 and ETV6 genes, suggesting that ACS2 is also involved in the pathogenesis of hematologic malignancies.
In previous studies, we have characterized ®ve ACSs Fujino and Yamamoto, 1992; Kang et al., 1997; Oikawa et al., 1998; Suzuki et al., 1990 ) that show dierent levels of expression in dierent tissues. ACS1, ACS2 and ACS5 are structurally similar enzymes that exhibit similar broad fatty acid preferences. Of these three enzymes, ACS5 is most abundant in intestinal epithelial cells, and is also highly expressed in undierentiated proliferating 3T3-L1 preadipocytes (Oikawa et al., 1998) . Since ACS1 and ACS2 are almost undetectable in proliferating 3T3-L1 preadipocytes, ACS5 may provide the acyl-CoA required for the synthesis of cellular lipids during cell proliferation (Oikawa et al., 1998) .
During characterization of the human ACS5 gene and transcripts, we found that: (i) the gene is located on chromosome 10q25.1-q25.2, a region frequently deleted in malignant gliomas (Bergerheim et al., 1991; Herbst et al., 1994; Karlbom et al., 1993; Peier et al., 1995; Rasheed et al., 1992 Rasheed et al., , 1995 ; and (ii) the levels of ACS5 mRNA are markedly increased in primary glioblastomas. Here we provide evidence that ACS5 mediates glioma cell growth by facilitating fatty acid transportation into cells.
Results

Molecular characterization of the human ACS5 gene
As an initial approach to evaluate the role of ACS5, we ®rst characterized the human ACS5 gene. A near full-length cDNA for human ACS5 was isolated from a human liver cDNA library using rat ACS5 cDNA (Oikawa et al., 1998) as a probe, and was completely sequenced (GeneBank Accession No. AB033899). The insert of the human ACS5 cDNA contains 154 nucleotides in the 5'-untranslated region, a 2052-nucleotide open reading frame encoding a protein of 683 amino acids with a calculated molecular weight of 75 957 and 1012 nucleotides in the 3'-untranslated region (Figure 1a) . Between human and rat ACS5, approximately 80% of the amino acids are identical. BLAST searches of the RHdb databases (http:// www.ebi.ac.uk/RHdb/) using the human ACS5 sequence reveal that the 3'-untranslated region contains a speci®c STS marker, WI-12237, which had been mapped to the q25.1-q25.2 region of chromosome 10.
To de®ne the genomic structure of the human ACS5 gene, we isolated and characterized two overlapping BAC clones [60(n16), 116(b1)] from a human BAC library (Genome Systems) and four YAC clones (816g5, 935g4, 950e11 and 962h2) from Mega YAC libraries (see Materials and methods). Characterization of these clones revealed that the gene overlaps with WI-12237, which has been placed approximately 0.5 cM telomeric of D10S1564 and spans approximately 46 kb, and encodes 21 exons (Figure 1b,c) . The 5'-untranslated region is encoded by exon 1, and a large intron of 15 kb separates it from exon 2, which contains the translation initiator codon AUG. Exon 21 contains the translation termination codon and the 3'-untranslated region. Functionally important luciferaselike regions (Suzki et al., 1990 , LR1 and LR2, are encoded by exons 7 ± 12 and exons 14 ± 19, respectively. The relevant sequence information is available under GenBank Accession Nos. AB033900 to AB033920.
Expression of ACS5 in human tissues and gliomas
Northern blotting of multiple tissue blots with the human ACS5 probe revealed two major transcripts of 2.5 and 3.7 kb in a wide range of human tissues, with the highest levels in uterus and spleen; relatively high levels in liver, small intestine, colon, and peripheral blood leukocytes; and lower levels in heart, lung, thymus and prostate (Figure 2a) . A trace amount of the mRNA was detected in brain, placenta, skeletal muscle, pancreas and kidney. In addition to the two transcripts with 2.5 and 3.7 kb, a unique transcript of 1.7 kb was detected only in testis. This major transcript in the testis may be a consequence of alternative splicing of pre-ACS5 mRNA, alternative transcription initiation of the ACS5 gene, degraded products of ACS5 mRNA, or an artifact of Northern blotting.
The location of the ACS5 gene, on chromosome region 10q25.1-25.2 region, is frequently deleted in malignant gliomas (Bergerheim et al., 1991; Herbst et al., 1994; Karlbom et al., 1993; Peier et al., 1995; Rasheed et al., 1992 Rasheed et al., , 1995 . Therefore, we analysed the levels of ACS5 transcripts in glioma cells and primary gliomas of various origins. Northern blotting of ACS5 transcripts in glioma cell lines A172, T98G, U251, U373MG and U87MG cells revealed an overproduction of ACS5 mRNA in A172 cells (Figure 2b ) with levels approximately 40-fold higher than those in normal brains. RNAs from cases of human primary gliomas of malignancy grade ranging from II to IV according to the WHO criteria were also analysed ( Figure 2c ). As shown in Figure 2d , the levels of the mRNA were signi®cantly higher in grade IV gliomas (P50.05, an average increase of 2.5-fold compared with normal brains). Furthermore, immunohistochemical analysis revealed signi®cant immunostaining with an anti-ACS5 antibody in primary glioblastomas, while only a trace of immunoreactivity was detected in the normal cerebral white matter ( Figure 3 ). We also analyzed the gene in patients with glioblastomas, however, there were no ampli®cations or rearrangements of the gene, except for a C to T substitution at nucleotide 111, which is also found in the normal populations.
Effects of ACS5 expression on cell growth and fatty acid uptake
To evaluate the eects of ACS5 expression on the growth of glioma cells, we constructed a recombinant adenovirus virus (designated AdACS5) containing the entire region of human ACS cDNA. U87MG cells, which showed the lowest expression of ACS5 mRNA among the ®ve glioma cell lines tested, were infected with 5 moi of AdACS5 or control AdlacZ viruses. To minimize the eects of FCS on the growth of glioma 30 mM palmitate, whereas almost no eects were observed on the growth of AdACS5 infected cells cultured in the absence of palmitate or AdlacZ infected cells in the absence or the presence of palmitate. A modest but signi®cant growth stimulation was also observed when uninfected A172 were exposed to 30 mM palmitate (data not shown). The maximal growth stimulation was observed at a palmitate concentration of 30 mM, the value close to the calculated K d of the puri®ed enzyme. However, at higher concentrations (460 mM) palmitate was toxic to the cells. In the presence of 10% FCS, the fatty acid induced growth induction was not detected, presumably because the presence of free fatty acid bound to serum albumin. The conditioned medium of AdACS5 infected U87MG cells exposed to palmitate had no growth stimulatory eects on uninfected cells (data not shown).
In the presence of palmitate, AdACS5 infected cells tended to form multilayered foci at a subcon¯uent density, whereas AdlacZ infected cells grew as a¯at monolayer (data not shown). Furthermore, DNA fragmentation analysis and TUNEL assay of glioma cells infected with AdACS5 or AdLacZ did not show any evidence of apoptosis (data not shown).
Similar fatty acid induced cell growth was also seen in A172, T98G, U251 and U87MG glioma cells stably transfected with an ACS5 expression plasmid (data not shown). In contrast to glioma cells, no growth stimulation was seen in Chinese hamster ovary, COS-6, HepG2, NIH3T3 or 3T3-L1 cells stably transfected with an ACS5 expression plasmid (data not shown). These data indicate that fatty acid-induced cell growth mediated by ACS5 is unique to glioma cells.
Regarding the speci®city of fatty acid on the induction of glioma cell growth, Figure 4D shows that exposure of the AdACS5 infected cells to myristate also induced cell growth, while essentially no eects were seen in the presence of oleate, linoleate or arachidonate.
To further de®ne the mechanism of fatty acid induced glioma cell growth, we analysed the uptake of [ 
Discussion
In the current studies, we have shown a novel growth induction of glioma cells mediated by ACS5. This growth induction may be of pathological signi®cance for the development and progression of malignant gliomas.
The primary function of ACS is to produce acylCoA for numerous metabolic pathways including cellular lipid metabolism, transcriptional regulation (Henry and Cronan, 1992; Hertz et al., 1998) , intracellular protein transportation (Glick and Rothman, 1987) , protein acylation (Grand, 1989) and protein kinase C mediated signal transduction (Bronfman et al., 1989) . A secondary function of ACS is that it facilitates fatty acid transportation into cells (Coe et Schaer and Lodish, 1994) . Consistent with the utilization of acyl-CoA in numerous metabolic pathways, there are multiple ACSs with distinct fatty acid speci®cities and dierent tissue distributions. Among the ®ve known ACSs, ACS5 is believed to provide acyl-CoA for the synthesis of cellular lipid during cell proliferation. Consistent with our hypothesis, the levels of ACS5 transcripts and proteins are markedly increased in malignant gliomas.
Although the ACS5 gene is located on chromosome 10q25.1-25.2 region, there were no apparent gene rearrangements in the primary gliomas and the ®ve glioma cell lines by Southern blotting. In contrast to the increment of ACS5 transcripts in primary glioblastomas, only a trace amount of the transcript was detected in glioma cell lines, T98G, U251, U373MG and U87MG. The sole exception was A172 cells, which exhibit 40-fold higher expression than those in the normal brain. This variation in glioma cell lines remains unknown.
U87MG cells infected with AdACS5 virus displayed induced cell growth by exposure to saturated fatty acids, palmitate and myristate, but not by unsaturated fatty acids including arachidonate and linolenate. This fatty acid induced cell growth mediated by ACS5 is unique to glioma cells (A172, T98G, U251 and U87MG cells), and was not observed in other cells, including Chinese hamster ovary, COS-6, HepG2, NIH3T3, or 3T3-L1 cells. Consistent with the induction of cell growth, U87MG cells infected with AdACS5 displayed induced uptake of palmitate, but did not show stimulation of arachidonate uptake, indicating that facilitated palmitate uptake may promote the induction of cell growth.
Although the mechanism(s) by which fatty acid induces glioma cell growth remain to be elucidated, there may be some relation with the intracellular fatty acid/acyl-CoA pool utilized for the synthesis of cellular lipids including membrane phospholipids. Pizer et al. (1998) have shown that inhibition of fatty acid synthase by its speci®c inhibitors, cerulenin and c75, results in the suppression of DNA replication and induces apoptosis in various tumor cell lines. Triacsins block the supply of acyl-CoAs, mainly for lipid synthesis, and also subsequently causes inhibition of cell growth (Tomoda et al., 1991) . These growth suppression eects by fatty acid synthase and ACS inhibitors apparently relate to the tumor cell phenotype of abnormally elevated fatty acid metabolism (Kuhajda et al., 1994; Tomoda et al., 1991) . The increased levels of ACS5 in malignant glioma may support the aggressive cell growth by increasing the size of the intracellular fatty acid/acyl-CoA pool.
In contrast to the increment of ACS5 in malignant gliomas, the ACS2 gene is disrupted by fusion of the ETV6 gene in myelodysplastic syndrome and acute myelogenous leukemia, suggesting that ACS2 acts as a tumor suppressor in hematopoietic cells (Yagasaki et al., 1999) . Together with our current data, it is suggested that the role of ACS5 in cell proliferation diers from that of ACS2. There may be a dierent fatty acid/acyl-CoA pool provided by ACS2 that may induce apoptosis in hematopoietic cells during dierentiation. Although further studies are necessary to demonstrate the exact roles of ACSs in cell proliferation, our current data have clearly demonstrated that ACS5 mediates novel fatty acid-induced glioma cell growth. 
Materials and methods
Molecular characterization of the human ACS5 gene, cDNA and transcripts
Standard molecular biology techniques were used (Sambrook et al., 1989) . DNA sequencing was performed by the dideoxy chain-termination method on an Applied Biosystems model 373A DNA sequencer. For Northern blotting, total RNA prepared by the guanidinium thiocyanate/CsCl method was fractionated in a 1.5% agarose gel, transferred to a Zeta Probe nylon membrane (Bio-Rad, Hercules, CA, USA), and hybridized with 32 P-labeled probes. Quantitative analysis was performed with an image analyzer (BAS2000, Fuji Film, Tokyo, Japan) and expressed as the intensity of phosphostimulated luminescence. A human ACS5 cDNA (designated phACS5) was obtained from a human liver cDNA library using the entire region of human rat ACS5 cDNA (Oikawa et al., 1998) (Cohen et al., 1993) , respectively. A set of human ACS5 speci®c primers [5'-CTTTCGGACCCAAATTGACAG-3' (nt. 2007 [5'-CTTTCGGACCCAAATTGACAG-3' (nt. ± 2027 of the (+) strand) and 5'-AAAGAAGAAGG-CACAGAGGGT-3' (nt 2392 ± 2412 of the (7) strand)] were used for PCR-based screening under the conditions recommended for Ex Taq TM (Takara Shuzo Corp., Kyoto, Japan). Intron sizes were determined by Southern blotting, restriction mapping and PCR of the genomic clones. DNA fragments carrying exons were identi®ed by restriction mapping and Southern blotting. After subcloning into pBluescript vectors, the sequences of exons, exon/intron boundaries and the 5'-anking region were determined.
Human gliomas
Human glioma samples were obtained from 31 patients (21 men and 10 women) of ages 14 ± 76 years at the time of surgical removal at the Department of Neurosurgery (Tohoku University School of Medicine). After obtaining written informed consent, DNA and RNA analyses were carried out, and these analyses were approved by the Institutional Review of Tohoku University School of Medicine. Total brain RNAs (four dierent lots) were obtained from Clontech laboratories, inc. (Palo Alto, CA, USA) and used as normal controls.
Antibodies, immunohistochemistry and immunoblotting
A 15-residue peptide corresponding to amino acid residues 72 to 86 was synthesized by Nippon Gene Research Laboratories (Sendai, Japan). The amino acid composition and sequence were con®rmed by the supplier. The peptide was coupled to keyhole limpet hemocyanin as described , and injected into rabbits according to the standard protocols (Harlow and Lane, 1988) . Immunohistochemical analysis of surgical specimens of grade IV malignant gliomas was performed on routinely processed, formalin-®xed, paran-embedded sections using a streptavidin-biotin complex method. The sections were autoclaved for 10 min before overnight incubation with a human ACS5 antibody (diluted 1 : 4000). The sections were washed and incubated with biotinylated secondary antibody (Histo®en SAB-PO (M) kit, Nichiei, Tokyo, Japan). Detection was performed using 3',3-diaminobenzidine tetrahydrochloride (DAB). Sections were counterstained with hematoxylin.
For immunoblotting, protein samples were separated on 8% SDS-polyacrylamide gels and transferred to polyvinylidine di¯uoride membrane (Bio-Rad). The membrane was blocked by incubation for 4 h with 3% gelatin in phosphate bued saline. The immunoblots were probed with human ACS5 antibody (diluted 1 : 2000) and bound antibody was detected by horseradish peroxidase-conjugated anti-rabbit immunoglobulin G using an Enhance Chemiluminescence (ECL) Western Blotting Detection Kit (Amersham Pharmacia Biotech. Inc.).
Generation of a recombinant adenovirus containing human ACS5 cDNA
An adenovirus (designated AdACS5) containing the entire region of human ACS5 cDNA was generated by multiple ligations of restriction fragments using an adenovirus expression vector kit (Takara Shuzo). A recombinant adenovirus AdlacZ which contains modi®ed chicken b-actin promoter with cytomegalovirus-immediate early promoter (Miyake et al., 1996) and the b-galactosidase gene was used as a control. AdACS5 and AdlacZ viruses were propagated in 293 cells, puri®ed by CsCl ultracentrifugation, and stored in PBS containing 10% (w/v) glycerol at 7808C, according to the manufacturer's instructions.
Cell culture, virus infection, cell proliferation assay and fatty acid uptake
All lines of Glioma cells were maintained in DMEM supplemented with 10% FCS. For cell proliferation and fatty acid uptake assays U87MG cells were plated in microtiter plates. On day 0, cells were plated at 1610 3 /well and grown in DMEM supplemented with 10% FCS for 18 h and then infected with 5 moi of adenoviruses and further incubated for 24 h. On day 2, the medium was replaced by DMEM supplemented with 2% FCS and 1% BSA (fatty acid free). On day 3, cells were exposed to fatty acids in DMEM supplemented with 2% FCS and 1% BSA and cultured for 3 ± 5 days for the cell proliferation assay. An MTS cell proliferation assay was performed using the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega Corp., Madison, WI, USA). For the fatty acid uptake assay, U87MG cells were cultured in DMEM supplemented with 10% FCS for 48 h after virus infection and washed with Dulbecco's complete (containing calcium and magnesium) phosphate buered saline (PBS) and incubated with PBS containing 20 mM BSA (fatty acid free) and 0.25 mM 
